对不处方不必要抗生素的儿童急性呼吸道和胃肠道感染实施经济激励的长期效果:日本全国准实验研究
日本2018年对3岁以下急性上呼吸道感染或胃肠炎患儿实施每例800日元(约5.7美元)的不处方抗生素理由申报激励。基于165113名儿童数据的错位双重差分与倾向评分匹配分析显示,激励引入后首月抗生素总处方减少44.9%(95%CI 41.1%-47.7%),48个月内减少19.5%(8.7%-29.1%),广谱抗生素同期减少24.4%(14.0%-33.6%),未增加住院、非工作时间就诊或医疗费用,但诊室就诊次数略有增加,约5次激励后抗生素使用下降趋于平缓。
要点
- 激励政策首月使抗生素总处方减少44.9%(95%CI 41.1%-47.7%)。
- 48个月内抗生素总处方减少19.5%(8.7%-29.1%),广谱抗生素减少24.4%(14.0%-33.6%)。
- 未增加住院、非工作时间就诊或医疗费用,诊室就诊次数略有增加。
核心结论
- 经济激励有效减少了儿童抗生素处方且未出现不良健康结局,4年内显示出持续获益。
- 该抗菌药物管理干预为其他国家遏制抗生素过度使用和应对抗菌药物耐药提供了可推广的模式。
研究设计与样本
- 采用错位双重差分设计结合倾向评分匹配的准实验研究。
- 数据来自2个全国行政数据库,纳入2017年4月至2019年3月出生的165113名儿童,随访至2022年5月。
- 比较暴露于该政策与未暴露的儿童。
主要发现
- 激励引入后首月抗生素总处方减少44.9%(95%CI 41.1%-47.7%)。
- 48个月内抗生素总处方减少19.5%(95%CI 8.7%-29.1%)。
- 同期广谱抗生素使用减少24.4%(95%CI 14.0%-33.6%)。
- 政策未导致住院、非工作时间就诊或医疗费用增加,但与诊室就诊次数略有增加相关。
- 观察到剂量-反应关系,抗生素使用下降在约5次激励后趋于平缓。
关键数值与推荐
- 政策允许符合条件的医疗机构对3岁以下急性上呼吸道感染或胃肠炎患儿,在提供不处方抗生素理由的情况下,每例申报800日元(约5.7美元)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To address antibiotic overuse, the Japanese government implemented a novel financial incentive policy in 2018. The policy enables eligible healthcare facilities to claim ¥800 (approximately $5.7) per case wherein a rationale to not prescribe antibiotics is offered for children aged <3 years with acute upper respiratory tract infections or gastroenteritis. Although the short-term effect of this policy was observed in our previous study, its long-term effects have not been evaluated nationwide. METHODS: We conducted a quasi-experimental study using a staggered difference-in-differences design with propensity score matching. Data from 165 113 children born between April 2017 and March 2019 were extracted from 2 nationwide administrative databases. The study tracked these children until May 2022, comparing those exposed to the policy with those who were not. RESULTS: The introduction of financial incentives led to a 44.9% reduction (95% confidence interval, 41.1%-47.7%) in total antibiotic prescriptions within the first month and 19.5% reduction (8.7%-29.1%) over 48 months. Broad-spectrum antibiotic use also decreased by 24.4% (95% confidence interval, 14.0%-33.6%) over the same period. The policy did not result in increased hospitalizations, after-hours visits, or healthcare costs, but it was associated with a slight increase in the number of office visits. A dose-response relationship was observed, with reductions in antibiotic use leveling off after approximately 5 incentives. CONCLUSIONS: Financial incentives effectively reduced antibiotic prescriptions in children without adverse health outcomes, demonstrating sustained benefits over 4 years. This antimicrobial stewardship intervention offers a scalable model for other countries aiming to curb antibiotic overuse and combat antimicrobial resistance.
引用
- Okubo Y, Uda K, Miyairi I, et al. Long-Term Effectiveness of Financial Incentives for Not Prescribing Unnecessary Antibiotics to Children With Acute Respiratory and Gastrointestinal Infections: Japan's Nationwide Quasi-Experimental Study. Clin Infect Dis. 2025. PMID: 39579079. doi:10.1093/cid/ciae577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。